Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond

Fuior, Elena Valeria; Gafencu, Anca Violeta

doi:10.3390/ijms20235939

Cited by 135 publications

(107 citation statements)

References 208 publications

(221 reference statements)

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Apolipoprotein C1 Part of multiple apolipoprotein complexes, has links to immune response and inflammation (Fuior and Gafencu, 2019) .…”

Section: Supplementary Informationmentioning

confidence: 99%

Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics

Messner

Demichev

Wendisch

et al. 2020

Preprint

View full text Add to dashboard Cite

The COVID-19 pandemic is an unprecedented global challenge. Highly variable in its presentation, spread and clinical outcome, novel point-of-care diagnostic classifiers are urgently required. Here, we describe a set of COVID-19 clinical classifiers discovered using a newly designed low-cost high-throughput mass spectrometry-based platform. Introducing a new sample preparation pipeline coupled with short-gradient high-flow liquid chromatography and mass spectrometry, our methodology facilitates clinical implementation and increases sample throughput and quantification precision. Providing a rapid assessment of serum or plasma samples at scale, we report 27 biomarkers that distinguish mild and severe forms of COVID-19, of which some may have potential as therapeutic targets. These proteins highlight the role of complement factors, the coagulation system, inflammation modulators as well as pro-inflammatory signalling upstream and downstream of Interleukin 6. Application of novel methodologies hence transforms proteomics from a research tool into a rapid-response, clinically actionable technology adaptable to infectious outbreaks. Highlights-A completely redesigned clinical proteomics platform increases throughput and precision while reducing costs.-27 biomarkers are differentially expressed between WHO severity grades for COVID-19.-The study highlights potential therapeutic targets that include complement factors, the coagulation system, inflammation modulators as well as pro-inflammatory signalling both upstream and downstream of interleukin 6.

show abstract

“…Apolipoprotein C1 Part of multiple apolipoprotein complexes, has links to immune response and inflammation (Fuior and Gafencu, 2019) .…”

Section: Supplementary Informationmentioning

confidence: 99%

Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics

Messner

Demichev

Wendisch

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…APOC1 is a member of the apolipoprotein family that ACTS not only to transport lipids and stabilize the lipoprotein structure but also to regulate pathological processes including diabetes, Alzheimer's and inflammation. [11][12][13][14] In recent years, some studies have found that ApoA1, 15,16 ApoB, [17][18][19] ApoE 20,21 and other apolipoproteins 22 are abnormally expressed in tumors and are related to the prognosis of patients. Therefore, the role of apolipoprotein family in the occurrence and development of tumors has attracted more attention.…”

Section: Introductionmentioning

confidence: 99%

<p>Apolipoprotein C1 (APOC1): A Novel Diagnostic and Prognostic Biomarker for Cervical Cancer</p>

Shi¹,

Wang²,

Dai³

et al. 2020

OTT

View full text Add to dashboard Cite

Background Previous reports showed that APOC1 was associated with several cancers but the function of APOC1 in cervical cancer was unknown. This study aimed to investigate the clinical effect and function of APOC1 in cervical cancer. Materials and Methods In this study, the relative expression of APOC1 in cervical cancer was detected by RT-qPCR. In order to determine the cell proliferation and migration and invading ability and apoptosis more accurately, we used CCK8 assay, Edu assay, wound healing assay, migration and invasion assay, flow cytometry assay, co-immunoprecipitation, proteomics and Western blot by silencing and overexpressing APOC1 , respectively. The role of APOC1 on tumor progression was explored in vitro and vivo. Results The relative expression of APOC1 in cervical cancer tissues was up-regulated (P<0.05). In cervical cancer cell lines, silencing of APOC1 restrained cell progression and EMT, while over-expression of APOC1 accelerated cell progression and EMT in vivo and vitro (P<0.05). Conclusion APOC1 acts as an oncogene in cervical cancers and knockdown of APOC1 inhibited cervical cancer cells growth in vitro and in vivo. There is a close relationship between the relative expression of APOC1 and clinical outcome in cervical cancer patients.

show abstract

“…Also, we detected the expression of lipid metabolism-related proteins, including Acat2 24 and LCAT. 25 Interestingly, miR-542-5p decreased the expression of Acat2 and elevated the expression of LCAT in primary hepatocytes and HepG2 cells, while anti-miR-542-5p exerted the opposite effects on the expression of Acat2 and LCAT ( Supplementary Fig. 1C , only online).…”

Section: Resultsmentioning

confidence: 93%

MiR-542-5p Inhibits Hyperglycemia and Hyperlipoidemia by Targeting FOXO1 in the Liver

et al. 2020

View full text Add to dashboard Cite

Purpose This research was designed to investigate how miR-542-5p regulates the progression of hyperglycemia and hyperlipoidemia. Materials and Methods An in vivo model with diabetic db/db mice and an in vitro model with forskolin/dexamethasone (FSK/DEX)-induced primary hepatocytes and HepG2 cells were employed in the study. Bioinformatics analysis was conducted to identify the expression of candidate miRNAs in the liver tissues of diabetic and control mice. H&E staining revealed liver morphology in diabetic and control mice. Pyruvate tolerance tests, insulin tolerance tests, and intraperitoneal glucose tolerance test were utilized to assess insulin resistance. ELISA was conducted to evaluate blood glucose and insulin levels. Red oil O staining showed lipid deposition in liver tissues. Luciferase reporter assay was used to depict binding between miR-542-5p and forkhead box O1 (FOXO1). Results MiR-542-5p expression was under-expressed in the livers of db/db mice. Further in vitro experiments revealed that FSK/DEX, which mimics the effects of glucagon and glucocorticoids, induced cellular glucose production in HepG2 cells and in primary hepatocytes cells. Notably, these changes were reversed by miR-542-5p. We found that transcription factor FOXO1 is a target of miR-542-5p. Further in vivo study indicated that miR-542-5p overexpression decreases FOXO1 expression, thereby reversing increases in blood glucose, blood lipids, and glucose-related enzymes in diabetic db/db mice. In contrast, anti-miR-542-5p exerted an adverse influence on blood glucose and blood lipid metabolism, and its stimulatory effects were significantly inhibited by sh-FOXO1 in normal control mice. Conclusion Collectively, our results indicated that miR-542-5p inhibits hyperglycemia and hyperlipoidemia by targeting FOXO1.

show abstract

Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond

Cited by 135 publications

References 208 publications

Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics

Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics

<p>Apolipoprotein C1 (APOC1): A Novel Diagnostic and Prognostic Biomarker for Cervical Cancer</p>

MiR-542-5p Inhibits Hyperglycemia and Hyperlipoidemia by Targeting FOXO1 in the Liver

Contact Info

Product

Resources

About